|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Abnet CC, Arnold M and Wei WQ:
Epidemiology of esophageal squamous cell carcinoma.
Gastroenterology. 154:360–373. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Gouw DJJM, Klarenbeek BR, Driessen M,
Bouwense SAW, van Workum F, Fütterer JJ, Rovers MM, Ten Broek RPG
and Rosman C: Detecting pathological complete response in
esophageal cancer after neoadjuvant therapy based on imaging
techniques: A diagnostic systematic review and meta-analysis. J
Thorac Oncol. 14:1156–1171. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Leng XF, Daiko H, Han YT and Mao YS:
Optimal preoperative neoadjuvant therapy for resectable locally
advanced esophageal squamous cell carcinoma. Ann N Y Acad Sci.
1482:213–224. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bolger JC, Donohoe CL, Lowery M and
Reynolds JV: Advances in the curative management of oesophageal
cancer. Br J Cancer. 126:706–717. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kumar A, Kumari N, Nallabelli N and Prasad
R: Pathogenic and therapeutic role of H3K4 family of methylases and
demethylases in cancers. Indian J Clin Biochem. 34:123–132. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
South PF, Fingerman IM, Mersman DP, Du HN
and Briggs SD: A conserved interaction between the SDI domain of
Bre2 and the Dpy-30 domain of Sdc1 is required for histone
methylation and gene expression. J Biol Chem. 285:595–607. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ali A and Tyagi S: Diverse roles of
WDR5-RbBP5-ASH2L-DPY30 (WRAD) complex in the functions of the SET1
histone methyltransferase family. J Biosci. 42:155–159. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang H, Shukla A, Wang X, Chen WY,
Bernstein BE and Roeder RG: Role for Dpy-30 in ES cell-fate
specification by regulation of H3K4 methylation within bivalent
domains. Cell. 144:513–525. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Simboeck E, Gutierrez A, Cozzuto L,
Beringer M, Caizzi L, Keyes WM and Di Croce L: DPY30 regulates
pathways in cellular senescence through ID protein expression. EMBO
J. 32:2217–2230. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang Z, Shah K, Khodadadi-Jamayran A and
Jiang H: Dpy30 is critical for maintaining the identity and
function of adult hematopoietic stem cells. J Exp Med.
213:2349–2364. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang Z, Augustin J, Chang C, Hu J, Shah K,
Chang CW, Townes T and Jiang H: The DPY30 subunit in SET1/MLL
complexes regulates the proliferation and differentiation of
hematopoietic progenitor cells. Blood. 124:2025–2033. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao T, Hong Y, Ming GL and Song H: Loss
of chromatin modulator Dpy30 compromises proliferation and
differentiation of postnatal neural stem cells. J Mol Cell Biol.
12:2–3. 2019.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee YJ, Han ME, Baek SJ, Kim SY and Oh SO:
Roles of DPY30 in the proliferation and motility of gastric cancer
cells. PLoS One. 10:e01318632015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang L, Zhang S, Li A, Zhang A, Zhang S
and Chen L: DPY30 is required for the enhanced proliferation,
motility and epithelial-mesenchymal transition of epithelial
ovarian cancer cells. Int J Mol Med. 42:3065–3072. 2018.PubMed/NCBI
|
|
16
|
He FX, Zhang LL, Jin PF, Liu DD and Li AH:
DPY30 regulates cervical squamous cell carcinoma by mediating
epithelial-mesenchymal transition (EMT). Onco Targets Ther.
12:7139–7147. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Paschalis A, Sheehan B, Riisnaes R,
Rodrigues DN, Gurel B, Bertan C, Ferreira A, Lambros MBK, Seed G,
Yuan W, et al: Prostate-specific membrane antigen heterogeneity and
DNA repair defects in prostate cancer. Eur Urol. 76:469–478. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hänzelmann S, Castelo R and Guinney J:
GSVA: Gene set variation analysis for microarray and RNA-seq data.
BMC Bioinformatics. 14:72013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yoshihara K, Shahmoradgoli M, Martinez E,
Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW,
Levine DA, et al: Inferring tumour purity and stromal and immune
cell admixture from expression data. Nat Commun. 4:26122013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin P, Tian P, Pang J, Lai L, He G, Song Y
and Zheng Y: Clinical significance of COL1A1 and COL1A2 expression
levels in hypopharyngeal squamous cell carcinoma. Oncol Lett.
20:803–809. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Smyth EC, Lagergren J, Fitzgerald RC,
Lordick F, Shah MA, Lagergren P and Cunningham D: Oesophageal
cancer. Nat Rev Dis Primers. 3:170482017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Allemani C, Matsuda T, Di Carlo V,
Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ,
Estève J, et al: Global surveillance of trends in cancer survival
2000-14 (CONCORD-3): Analysis of individual records for 37 513 025
patients diagnosed with one of 18 cancers from 322 population-based
registries in 71 countries. Lancet. 391:1023–1075. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu B: DPY30 functions in glucose
homeostasis via integrating activated histone epigenetic
modifications. Biochem Biophys Res Commun. 507:286–290. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hong ZF, Zhang WQ, Wang SJ, Li SY, Shang
J, Liu F and Shen DY: Upregulation of DPY30 promotes cell
proliferation and predicts a poor prognosis in cholangiocarcinoma.
Biomed Pharmacother. 123:1097662020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang X, Lou Z, Dong X, Yang W, Peng Y, Yin
B, Gong Y, Yuan J, Zhou W, Bartlam M, et al: Crystal structure of
the C-terminal domain of human DPY-30-like protein: A component of
the histone methyltransferase complex. J Mol Biol. 390:530–537.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dou Y, Milne TA, Ruthenburg AJ, Lee S, Lee
JW, Verdine GL, Allis CD and Roeder RG: Regulation of MLL1 H3K4
methyltransferase activity by its core components. Nat Struct Mol
Biol. 13:713–719. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Song Y, Wu F and Wu J: Targeting histone
methylation for cancer therapy: Enzymes, inhibitors, biological
activity and perspectives. J Hematol Oncol. 9:492016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang Z, Shah K, Busby T, Giles K,
Khodadadi-Jamayran A, Li W and Jiang H: Hijacking a key chromatin
modulator creates epigenetic vulnerability for MYC-driven cancer. J
Clin Invest. 128:3605–3618. 2018. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shah KK, Whitaker RH, Busby T, Hu J, Shi
B, Wang Z, Zang C, Placzek WJ and Jiang H: Specific inhibition of
DPY30 activity by ASH2L-derived peptides suppresses blood cancer
cell growth. Exp Cell Res. 382:1114852019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chockley PJ and Keshamouni VG:
Immunological consequences of epithelial-mesenchymal transition in
tumor progression. J Immunol. 197:691–698. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lu K, Tao H, Si X and Chen Q: The histone
H3 lysine 4 presenter WDR5 as an oncogenic protein and novel
epigenetic target in cancer. Front Oncol. 8:5022018. View Article : Google Scholar : PubMed/NCBI
|
